Cover Image
市場調查報告書

藥物輸送設備的全球市場:市場分析,企業簡介,市場規模,市場佔有率,成長,市場趨勢,市場預測

Global Drug Delivery Devices Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

出版商 Data Bridge Market Research Private Limited 商品編碼 536487
出版日期 內容資訊 英文 350 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物輸送設備的全球市場:市場分析,企業簡介,市場規模,市場佔有率,成長,市場趨勢,市場預測 Global Drug Delivery Devices Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
出版日期: 2017年12月01日 內容資訊: 英文 350 Pages
簡介

本報告提供藥物輸送設備的全球市場調查,市場概要,各產品類型、終端用戶、流通管道、地區的市場趨勢,市場規模的變化與預測,市場未來展望,競爭情形,主要企業簡介等,總括性彙整。

第1章 簡介

第2章 調查手法

第3章 市場概要

第4章 摘要整理

第5章 重要考察

第6章 藥物輸送設備市場:產品類型

  • 市場概要
  • 口服給藥型藥物輸送
    • 口服固態劑
    • 口服液劑
    • 半固態劑
  • 肺部藥物遞輸
    • 定量噴霧吸入器(MDI)
    • 乾粉式吸入器(DPI)
    • 噴霧器
  • 注射型藥物輸送
    • 傳統注射器
    • 自行注射器
    • 無針注射器
    • 自動注射器
    • 筆型注射器
    • 穿戴式注射器
    • 其他
  • 鼻腔給藥
    • 點鼻子液
    • 鼻噴霧
    • 點鼻子粉劑
    • 點鼻子凝膠
  • 局部藥物輸送
  • 植入式藥物輸送
  • 口腔粘膜吸收型藥物輸送

第7章 藥物輸送設備市場:各終端用戶

  • 市場概要
  • 醫院
  • 居家照護
  • 診療所
  • 地區醫療
  • 其他

第8章 藥物輸送設備市場:各流通管道

  • 市場概要
  • 醫院內藥局
  • 藥局
  • 直接競標
  • 線上藥局

第9章 藥物輸送設備市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 土耳其
    • 比利時
    • 荷蘭
    • 瑞士
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 韓國
    • 印度
    • 澳洲
    • 新加坡
    • 泰國
    • 馬來西亞
    • 印尼
    • 菲律賓
    • 其他
  • 南美
    • 巴西
    • 其他
  • 中東、非洲
    • 南非
    • 其他
  • 主要國家的考察

第10章 競爭情形

  • 企業的市場佔有率:全地區
  • 企業的市場佔有率:美國
  • 企業的市場佔有率:歐洲
  • 企業的市場佔有率:亞太地區

第11章 企業簡介

  • BAYER AG
  • JOHNSON & JOHNSON
  • NOVARTIS AG
  • PFIZER, INC.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • MERCK & CO.
  • ANTARES PHARMA, INC.
  • 3M
  • SANOFI
  • NEMERA

第12章 附錄

第13章 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Title:
Global Drug Delivery Devices Market
By Route of Administration (Oral, Injectable, Topical, Pulmonary, Nasal, Ocular, Implantable, Transmucosal), End-User (Hospitals, Clinics, Home Care Settings), Distribution Channel (Direct Tenders,Hospital Pharmacies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa) - Trends and Forecast To 2024.

In this region, Global Drug Delivery Devices Market projected to USD 1,027.0 billion in 2016 growing at a CAGR of 8.1% during the forecast period of 2017 to 2024..

Based on geography, the global Drug Delivery Devices market is segmented into 5 geographical regions, such as,

  • North America,
  • South America,
  • Europe,
  • Asia-pacific,
  • Middle East and Africa .

Global Drug Delivery Devices market competition by top players including -

  • 3M Company,
  • Merck & Co., Inc.,
  • Pfizer Inc,
  • Johnson & Johnson,
  • Pfizer, Inc.,
  • Bayer AG,
  • F. Hoffmann-La Roche AG,
  • Sanofi,
  • Alkermes,
  • Abbott,
  • Novartis AG,
  • Valeant Pharmaceuticals International, Inc.,
  • Mylan Pharmaceuticals Inc.,
  • Antares Pharma,
  • Skye Pharma Plc.,
  • Nova Nordisk A/S,
  • Crossject,
  • Eli Lilly and Company,
  • Baxter International, Inc.,
  • Becton, Dickinson and Company,
  • Skyepharma AG

By product type, the global drug delivery devices market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable and transmucosal.

Oral Drug Delivery is then segmented on the basis of form into solid oral drugs, liquid oral drugs and semi-solid oral drugs. The form of solid oral drugs is further sub segmented into tablets, capsules, powders, and pills.

Liquid oral drug is sub segmented into solutions and syrups.Semi-solid oral drug is sub segmented into gels, emulsions and elixirs.

Pulmonary Drug Delivery is segmented on the basis of formulations, devices and nebulizers.

On the basis of device the pulmonary drug delivery segment is further sub-segmented into in metered dose inhalers and dry powder inhaler.Nebulizers are sub segmented into Jet Nebulizers, Ultrasonic Nebulizers and Soft Mist Nebulizers.

The injectable drug delivery segment is further segmented on the basis of product type and formulations.

On the basis of type, the injectable drug delivery is segmented into self-injection devices, needle free injectors, auto-injectors, pen-injectors, wearable injectors.

On the basis of formulations the market is segmented into conventional drug delivery formulations, novel drug delivery formulations and long acting injection formulations.

The ophthalmic drug delivery is segmented on the basis of product type - ocular drug delivery devices and ocular drug delivery formulations.

The ocular drug delivery is further segmented by product type, drug coated contact lenses and ocular inserts.

The ocular drug delivery formulations is further segmented into liquid ocular drug delivery formulations and semi-solid ocular drug delivery formulations.

On the basis of type the liquid ocular drug delivery formulations is further sub segmented into eye drops and sprays.

On the basis of type the semi-solid ocular drug delivery formulations is sub segmented into gels and ointments.

The nasal drug delivery is segmented by type in nasal drops, nasal sprays, nasal powders and nasal gels.

The topical drug delivery is segmented on the basis of product type, transdermal drug delivery devices and topical drug delivery formulations.

On the basis of product type the transdermal drug delivery devices is further sub segmented in transdermal patches and transdermal gels.

On the basis of forms the topical drug delivery formulations are sub segmented into liquid topical drug delivery formulations, semi-solid topical drug delivery formulations, and solid topical drug delivery formulations.

The liquid topical drug delivery formulations are further sub segmented into solutions and suspensions.

The semi-solid topical drug delivery formulations are further sub segmented by type into creams, gels, ointments, pastes and lotions.

On the basis of type the solid topical drug delivery formulations is further sub segmented into suppositories and powders.

The implantable drug delivery is segmented by product type, active implantable drug delivery and passive implantable drug delivery.

On the basis of product type the transmucosal drug delivery is segmented in oral transmucosal drug delivery and other transmucosal drug delivery.

On the basis of type the oral transmucosal drug delivery is further sub segmented into buccal drug delivery and sublingual drug delivery.

The other transmucosal drug delivery is further sub segmented into rectal transmucosal drug delivery and vaginal transmucosal drug delivery.

On the basis of end users the market is segmented into hospitals, home healthcare, clinics, community healthcare and others.

On the basis of distribution channel the market is segmented in hospital pharmacies, pharmacy stores and direct tenders.

Table of Contents

1. INTRODUCTION

  • 1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
  • 1.2. CURRENCY AND PRICING
  • 1.3. LIMITATION
  • 1.4. MARKETS COVERED

2. RESEARCH METHODOLOGY

  • 2.1. MARKETS IN DRUG DELIVERY DEVICES MARKET
  • 2.2. GEOGRAPHICAL SCOPE
  • 2.3. YEARS CONSIDERED IN THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
    • 2.5.1. MARKET CRACKDOWN APPROACH
    • 2.5.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
    • 2.5.3. DATA TRIANGULATION
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

  • 6.1. OVERVIEW
  • 6.2. ORAL DRUG DELIVERY, BY FORM
    • 6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
      • 6.2.1.1. TABLETS
      • 6.2.1.2. CAPSULES
      • 6.2.1.3. POWDER
      • 6.2.1.4. PILLS
    • 6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
      • 6.2.2.1. SOLUTIONS
      • 6.2.2.2. SYRUPS
    • 6.2.3. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
      • 6.2.3.1. GELS
      • 6.2.3.2. EMULSIONS
      • 6.2.3.3. ELIXIRS
  • 6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
    • 6.3.1. METERED DOSE INHALERS (MDI)
    • 6.3.2. DRY POWDER INHALERS (DPI)
    • 6.3.3. NEBULIZERS
      • 6.3.3.1. JET NEBULIZERS
      • 6.3.3.2. ULTRASONIC NEBULIZERS
      • 6.3.3.3. SOFT MIST NEBULIZERS
  • 6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
    • 6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE
      • 6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
        • 6.4.1.1.1. GLASS
        • 6.4.1.1.2. PLASTIC
      • 6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
        • 6.4.2.2.1. FILLABLE
        • 6.4.2.2.2. PRE-FILLED
      • 6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
        • 6.4.3.3.1. REUSABLE SYRIGES
        • 6.4.3.3.2. DISPOSABLE SYRINGES
      • 6.4.3.4. SELF INJECTION DEVICES
      • 6.4.3.5. NEEDLE FREE INJECTORS
      • 6.4.3.6. AUTOINJECTORS
      • 6.4.3.7. PEN INJECTORS
      • 6.4.3.8. WEARABLE INJCTORS
      • 6.4.3.9. OTHERS
    • 6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
      • 6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
      • 6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
      • 6.4.2.3. LONG ACTING INJECTION FORMULATIONS
  • 6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
    • 6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
      • 6.5.1.1. DRUG COATED CONTACT LENSES
      • 6.5.1.2. OCCULAR INSERTS
    • 6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
      • 6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.5.2.1.1. EYE DROPS
        • 6.5.2.1.2. SPRAYS
      • 6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.5.2.2.1. GELS
        • 6.5.2.2.2. OINTMENTS
  • 6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
    • 6.6.1. NASAL DROPS
    • 6.6.2. NASAL SPRAYS
    • 6.6.3. NASAL POWDERS
    • 6.6.4. NASAL GELS
  • 6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
    • 6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
      • 6.7.1.1. TRANSDERMAL PATCHES
      • 6.7.1.2. TRANSDERMAL GELS
    • 6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
      • 6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.7.2.1.1. SOLUTIONS
        • 6.7.2.1.2. SUSPENSIONS
      • 6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.7.2.2.1. GELS
        • 6.7.2.2.2. CREAMS
        • 6.7.2.2.3. OINTMENTS
        • 6.7.2.2.4. PASTES
        • 6.7.2.2.5. LOTIONS
      • 6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.7.2.3.1. SUPPOSITORIES
        • 6.7.2.3.2. POWDERS
  • 6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE
    • 6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
    • 6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
  • 6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE
    • 6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE
      • 6.9.1.1. BUCCAL DRUG DELIVERY
      • 6.9.1.2. SUBLINGUAL DRUG DELIVERY
    • 6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE
      • 6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY
      • 6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY

7. DRUG DELIVERY DEVICES MARKET, BY END-USER

  • 7.1. OVERVIEW
  • 7.2. HOSPITALS
  • 7.3. HOME HEALTHCARE
  • 7.4. CLINICS
  • 7.5. COMMUNITY HEALTHCARE
  • 7.6. OTHERS

8. DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

  • 8.1. OVERVIEW
  • 8.2. HOSPITAL PHARMACIES
  • 8.3. PHARMACY STORES
  • 8.4. DIRECT TENDERS
  • 8.5. ONLINE PHARMACY

9. DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY

  • 9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
    • 9.1.1. NORTH AMERICA
      • 9.1.1.1. U.S.
      • 9.1.1.2. CANADA
      • 9.1.1.3. MEXICO
    • 9.1.2. EUROPE
      • 9.1.2.1. GERMANY
      • 9.1.2.2. FRANCE
      • 9.1.2.3. U.K.
      • 9.1.2.4. ITALY
      • 9.1.2.5. SPAIN
      • 9.1.2.6. RUSSIA
      • 9.1.2.7. TURKEY
      • 9.1.2.8. BELGIUM
      • 9.1.2.9. NETHERLANDS
      • 9.1.2.10. SWITZERLAND
      • 9.1.2.11. REST OF EUROPE
    • 9.1.3. ASIA-PACIFIC (APAC)
      • 9.1.3.1. JAPAN
      • 9.1.3.2. CHINA
      • 9.1.3.3. SOUTH KOREA
      • 9.1.3.4. INDIA
      • 9.1.3.5. AUSTRALIA
      • 9.1.3.6. SINGAPORE
      • 9.1.3.7. THAILAND
      • 9.1.3.8. MALAYSIA
      • 9.1.3.9. INDONESIA
      • 9.1.3.10. PHILIPPINES
      • 9.1.3.11. REST OF APAC
    • 9.1.4. LATIN AMERICA
      • 9.1.4.1. BRAZIL
      • 9.1.4.2. REST OF LATIN AMERICA
    • 9.1.5. MIDDLE EAST AND AFRICA
      • 9.1.5.1. SOUTH AFRICA
      • 9.1.5.2. REST OF MIDDLE EAST AND AFRICA
  • 9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

10. DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE

  • 10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS

11. DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES

  • 11.1. BAYER AG
    • 11.1.1. COMPANY OVERVIEW
    • 11.1.2. REVENUE ANALYSIS
    • 11.1.3. PRODUCT PORTFOLIO
    • 11.1.4. RECENT DEVELOPEMENTS
    • 11.1.5. DATA BRIDGE ANALYSIS
  • 11.2. JOHNSON & JOHNSON
    • 11.2.1. COMPANY OVERVIEW
    • 11.2.2. REVENUE ANALYSIS
    • 11.2.3. PRODUCT PORTFOLIO
    • 11.2.4. RECENT DEVELOPEMENTS
    • 11.2.5. DATA BRIDGE ANALYSIS
  • 11.3. NOVARTIS AG
    • 11.3.1. COMPANY OVERVIEW
    • 11.3.2. REVENUE ANALYSIS
    • 11.3.3. PRODUCT PORTFOLIO
    • 11.3.4. RECENT DEVELOPEMENTS
    • 11.3.5. DATA BRIDGE ANALYSIS
  • 11.4. PFIZER, INC.
    • 11.4.1. COMPANY OVERVIEW
    • 11.4.2. REVENUE ANALYSIS
    • 11.4.3. PRODUCT PORTFOLIO
    • 11.4.4. RECENT DEVELOPEMENTS
    • 11.4.5. DATA BRIDGE ANALYSIS
  • 11.5. F. HOFFMANN-LA ROCHE AG
    • 11.5.1. COMPANY OVERVIEW
    • 11.5.2. REVENUE ANALYSIS
    • 11.5.3. PRODUCT PORTFOLIO
    • 11.5.4. RECENT DEVELOPEMENTS
    • 11.5.5. DATA BRIDGE ANALYSIS
  • 11.6. GLAXOSMITHKLINE PLC
    • 11.6.1. COMPANY OVERVIEW
    • 11.6.2. REVENUE ANALYSIS
    • 11.6.3. PRODUCT PORTFOLIO
    • 11.6.4. RECENT DEVELOPEMENTS
    • 11.6.5. DATA BRIDGE ANALYSIS
  • 11.7. MERCK & CO.
    • 11.7.1. COMPANY OVERVIEW
    • 11.7.2. REVENUE ANALYSIS
    • 11.7.3. PRODUCT PORTFOLIO
    • 11.7.4. RECENT DEVELOPEMENTS
    • 11.7.5. DATA BRIDGE ANALYSIS
  • 11.8. ANTARES PHARMA, INC.
    • 11.8.1. COMPANY OVERVIEW
    • 11.8.2. REVENUE ANALYSIS
    • 11.8.3. PRODUCT PORTFOLIO
    • 11.8.4. RECENT DEVELOPEMENTS
    • 11.8.5. DATA BRIDGE ANALYSIS
  • 11.9. 3M
    • 11.9.1. COMPANY OVERVIEW
    • 11.9.2. REVENUE ANALYSIS
    • 11.9.3. PRODUCT PORTFOLIO
    • 11.9.4. RECENT DEVELOPEMENTS
    • 11.9.5. DATA BRIDGE ANALYSIS
  • 11.10. SANOFI
    • 11.10.1. COMPANY OVERVIEW
    • 11.10.2. REVENUE ANALYSIS
    • 11.10.3. PRODUCT PORTFOLIO
    • 11.10.4. RECENT DEVELOPEMENTS
    • 11.10.5. DATA BRIDGE ANALYSIS
  • 11.11. NEMERA
    • 11.11.1. COMPANY OVERVIEW
    • 11.11.2. REVENUE ANALYSIS
    • 11.11.3. PRODUCT PORTFOLIO
    • 11.11.4. RECENT DEVELOPEMENTS
    • 11.11.5. DATA BRIDGE ANALYSIS

12. APPENDIX

13. DISCLAIMER

Back to Top